BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5.

Andrea Visentin^{1

2}, Silvia Imbergamo¹, Edoardo Scomazzon¹, Stefano Pravato¹, Federica Frezzato^{1

2}, Laura Bonaldi³, Marco Pizzi⁴, Stefania Vio⁵, Michele Gregianin⁶, Marta Burei⁷, Monica Facco^{1

2}, Gianpietro Semenzato^{1

2}, Francesco Piazza^{1

2}, Livio Trentin^{1

2}

¹ Haematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
² Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica Avanzata, Padua, Italy.
³ Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy.
⁴ General Pathology & Cytopathology Unit, Department of Medicine, University of Padua, Padua, Italy.
⁵ Radiology Unit, University Hospital of Padua, Padua, Italy.
⁶ Nuclear Medicine unit, San Giacomo Hospital, Castelfranco Veneto, Italy.
⁷ Nuclear Medicine unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy.

No abstract available

Keywords: chronic lymphocytic leukaemia; ibrutinib; idelalisib; lenalidomide; richter syndrome.

Publication types